EA Pharma licenses rights to AJT-240 in China to Tasly Pharmaceutical

**Torreya advised EA Pharma on the license of AJT-240**

Tokyo, Japan and Tianjin, China, June 11, 2018

EA Pharmaceutical Co., Ltd., the gastrointestinal disease area subsidiary of Eisai Co., Ltd., signed a licensing agreement for the commercialization of AJT-240 in China with Tasly Pharmaceutical Group, Co. AJT-240 is an allosteric modifier for calcium sensing receptors to treat secondary hyperparathyroidism caused by end-stage renal impairment and hemodialysis. AJT-240 has completed multicenter clinical phase I/II(a) clinical trials. Tasly will carry out development, manufacturing and commercialization of AJT-240 in Greater China. EA Pharma will receive $3 million in upfront payment and $21 million in development milestones, as well as 10% royalty payments based on annual net sales.

Hypertension and diabetes mellitus are the main causes of chronic kidney disease, and the pathological development of chronic kidney disease can also cause complications of chronic diseases such as hypertension and diabetes. AJT240 will help enrich Tasly’s existing diabetes, cardiovascular and cerebrovascular related therapeutic product portfolio, and further expand the entire product pipeline for chronic disease market.

Torreya served as financial advisor to EA pharma on this transaction. This transaction reinforces Torreya’s strength and leadership position as an advisor in the China market. Torreya has advised on 12 strategic and financing transactions in the life sciences industry in 2018 year to date.

**ABOUT EA PHARMACEUTICAL CO., LTD.**
For more information about EA Pharmaceutical Co., Ltd., please see: [www.eapharma.co.jp/en](http://www.eapharma.co.jp/en)

**ABOUT TASLY PHARMACEUTICAL GROUP, CO.**
For more information about Tasly Pharmaceutical Group, Co., please see: [www.taslyint.com](http://www.taslyint.com)

Deal Press Release

**Torreya Contact**

**JIE LIU**
Managing Director | New York Office
jie.liu@torreya.com | 917.683.4003 | [torreya.com](http://torreya.com)

Torreya is a global advisory firm serving the life sciences industry. Please visit [torreya.com](http://torreya.com) for more information. Securities offered in the United States are offered through Torreya Capital LLC, Member FINRA/SIPC. Torreya Partners LLC is a Delaware Limited Liability Company while Torreya Partners (Europe) LLP is a limited liability partnership, registered in England and Wales, registered number OC362930. Registered office: 150 Aldersgate Street, London EC1A 4AB. Torreya Partners (Europe) LLP is authorized and regulated by the Financial Conduct Authority. The information contained in the email and/or its attachments is confidential and/or privileged and is for the sole use of the intended recipient(s). If you are not the intended recipient, please notify the sender immediately by reply and immediately delete this message and all its attachments. Any review, use, reproduction, disclosure or dissemination of the message or any attachment by an unintended recipient is strictly prohibited. Neither this message nor any attachment is intended as or should be construed as an offer, solicitation or recommendation to buy or sell any security or other financial instrument. This communication is for informational purposes only. All investments involve risks including loss of principal invested. Past performance does not guarantee future results or success. Torreya Capital and its representatives do not provide tax or legal advice and each tax and financial situation is unique. Investors should consult their tax and/or legal advisor for advice and information concerning their particular situation.